We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dendritic cell-cytokine killer combined with microwave ablation reduced recurrence for hepatocellular carcinoma compared to ablation alone.
- Authors
Wang, Luo; Li, Xin; Dong, Xue-Juan; Yu, Xiao-Ling; Zhang, Jing; Cheng, Zhi-Gang; Han, Zhi-Yu; Liu, Fang-Yi; Yu, Jie; Liang, Ping
- Abstract
BACKGROUND: Several international practice guidelines have recommended local ablation as the first-line treatment for early-stage hepatocellular carcinoma (HCC). OBJECTIVE: This study aims to investigate the synergetic anti-tumor impact of dendritic cell-cytokine killer (DC-CIK) combined with microwave ablation (MWA) for HCC. METHODS: This retrospective study included 1,141 patients from the American Joint Committee on Cancer stage I-II HCC, who were treated with therapeutic MWA. The immunotherapy group encompassing 40 patients received additional immunotherapy with DC-CIK, whereas the control group consisting of 1,101 patients was treated with MWA alone. Propensity score matching (PSM) with ratio of 1:3 was employed to balance selection bias. The oncological outcome and immune status were measured after combination therapy. RESULTS: The immunotherapy group patients exhibited significant longer disease-free survival (DFS, primary HCC: p = 0.036; recurrent HCC: p = 0.026). For patients with primary HCC, the recurrence frequency was reduced (p = 0.002), and recurrence interval (19 months vs. 9 months, p < 0.001) was prolonged in the immunotherapy group. Subgroup analysis revealed that patients ⩽ 60 years old, moderately-differentiated HCC, or co-infected with Hepatitis B Virus (HBV) had a significant benefit over DFS in the immunotherapy group. After combination therapy, the serum CD3 + (p = 0.049), CD8/CD28 + (p = 0.045) were elevated. CONCLUSION: Combination therapy with DC-CIK and MWA can significantly reduce the recurrence and prolong DFS, especially for patients ⩽ 60 years old or with moderately-differentiated HCC or co-infected with HBV.
- Subjects
PROPENSITY score matching; HEPATITIS B virus; IMMUNITY; MICROWAVES; PROGRESSION-free survival; HEPATOCELLULAR carcinoma
- Publication
Technology & Health Care, 2024, Vol 32, Issue 3, p1819
- ISSN
0928-7329
- Publication type
Article
- DOI
10.3233/THC-230871